KSC · 207940.KS
Samsung Biologics Co.,Ltd.
₩1,448,500+₩82,500 (+6.04%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.08% below the high.
Loading market information…
KSC · 326030.KS · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 05:25 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
SK Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 45.94% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
SK Biopharmaceuticals Co., Ltd.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of ₩758. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow SK Biopharmaceuticals Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | ₩298-16.18% vs estimate | ₩144.38B-8.07% vs estimate |
|---|
| Q4 2024 | Feb 6, 2025 | ₩2,428+925.01% vs estimate | ₩163.02B+3.18% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | ₩123-33.48% vs estimate | ₩136.6B+3.88% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩1,448,500+₩82,500 (+6.04%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.08% below the high.
₩192,000+₩2,700 (+1.43%)
Celltrion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.76% below the high.
₩211,500-₩8,500 (-3.86%)
Alteogen Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.45% below the high.
₩39,050-₩1,950 (-4.76%)
ABL Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.82% below the high.
₩94,300-₩2,200 (-2.28%)
OliX Pharmaceuticals,Inc’s quoted price sits in the lower half of its reported 52-week range, 56.54% below the high.
₩106,500-₩8,700 (-7.55%)
Voronoi, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.56% below the high.
₩40,750-₩950 (-2.28%)
D&D Pharmatech’s quoted price sits in the lower half of its reported 52-week range, 65.01% below the high.
₩36,450-₩50 (-0.14%)
Oscotec Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.77% below the high.
